{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:54:35Z","timestamp":1792446875831,"version":"4.5.0"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0027_s_001_w2aab3b7c10b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal duration of antibiotic treatment for complicated parapneumonic effusions (CPPEs) has not been properly defined. Our aim was to compare the efficacy of amoxicillin-clavulanate for 2 vs. 3\u2006weeks in patients with CPPE (i.e. those which required chest tube drainage).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0027_s_002_w2aab3b7c10b1b6b1aab1c14b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this non-inferiority, randomized, double-blind, controlled trial, patients with community-acquired CPPE were recruited from two centers in Spain and, after having obtained clinical stability following 2\u2006weeks of amoxicillin-clavulanate, they were randomly assigned to placebo or antibiotic for an additional week. The primary objective was clinical success, tested for a non-inferiority margin of&lt;10%. Secondary outcomes were the proportion of residual pleural thickening of&gt;10\u2006mm at 3\u2006months, and adverse events. The study was registered with EudraCT, number 2014-003137-25. We originally planned to randomly assign 284 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0027_s_003_w2aab3b7c10b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After recruiting 55 patients, the study was terminated early owing to slow enrolment. A total of 25 patients were assigned to 2\u2006weeks and 30 patients to 3\u2006weeks of amoxicillin-clavulanate. Clinical success occurred in the 25 (100%) patients treated for 2\u2006weeks and 29 (97%) treated for 3\u2006weeks (difference 3%, 95% CI \u22123 to 9.7%). Respective between-group differences in the rate of residual pleural thickening (\u221212%, 95%CI \u221239 to 14%) and adverse events (\u22127%, 95%CI \u221216 to 2%) did not reach statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0027_s_004_w2aab3b7c10b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this small series of selected adult patients with community-acquired CPPE, amoxicillin-clavulanate treatment could be safely discontinued by day 14 if clinical stability was obtained.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0027","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T04:03:04Z","timestamp":1582776184000},"source":"Crossref","is-referenced-by-count":26,"title":["Two vs. three weeks of treatment with amoxicillin-clavulanate for stabilized community-acquired complicated parapneumonic effusions. A preliminary non-inferiority, double-blind, randomized, controlled trial"],"prefix":"10.1515","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-8061","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Porcel","sequence":"first","affiliation":[{"name":"Pleural Medicine Unit, Department of Internal Medicine , Arnau de Vilanova University Hospital, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ferreiro","sequence":"additional","affiliation":[{"name":"Department of Pulmonology , University Clinical Hospital of Santiago, Health Research Institute of Santiago de Compostela (IDIS) , A Coru\u00f1a , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Arnau de Vilanova University Hospital, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Espino-Pais\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Hospital de Barbanza , A Coru\u00f1a , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Civit","sequence":"additional","affiliation":[{"name":"Pleural Medicine Unit, Department of Internal Medicine , Arnau de Vilanova University Hospital, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pardina","sequence":"additional","affiliation":[{"name":"Department of Radiology , Arnau de Vilanova University Hospital, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Schoenenberger-Arnaiz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Arnau de Vilanova University Hospital, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Vald\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Pulmonology , University Clinical Hospital of Santiago, Health Research Institute of Santiago de Compostela (IDIS) , A Coru\u00f1a , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bielsa","sequence":"additional","affiliation":[{"name":"Pleural Medicine Unit, Department of Internal Medicine , Arnau de Vilanova University Hospital, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"2025120909224052144_j_pp-2019-0027_ref_001_w2aab3b7c10b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Falguera M, Carratal\u00e0 J, Bielsa S, Garc\u00eda-Vidal C, Ruiz-Gonz\u00e1lez A, Chica I, et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J 2011;38:1173\u20139.","DOI":"10.1183\/09031936.00000211"},{"key":"2025120909224052144_j_pp-2019-0027_ref_002_w2aab3b7c10b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45\u2013e67.","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"2025120909224052144_j_pp-2019-0027_ref_003_w2aab3b7c10b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Brims F, Popowicz N, Rosenstengel A, Hart J, Yogendran A, Read CA, et al. Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia: A 6-year analysis. Respirology 2019;24:171\u20138.","DOI":"10.1111\/resp.13395"},{"key":"2025120909224052144_j_pp-2019-0027_ref_004_w2aab3b7c10b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Hassan M, Cargill T, Harriss E, Asciak R, Mercer RM, Bedawi EO, et al. The microbiology of pleural infection in adults: a systematic review. Eur Respir J 2019;54:3.","DOI":"10.1183\/13993003.00542-2019"},{"key":"2025120909224052144_j_pp-2019-0027_ref_005_w2aab3b7c10b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Wrightson JM, Wray JA, Street TL, Chapman SJ, Gleeson FV, Maskell NA, et al. Absence of atypical pathogens in pleural infection. Chest 2015;148:e102\u2013e103.","DOI":"10.1378\/chest.15-1130"},{"key":"2025120909224052144_j_pp-2019-0027_ref_006_w2aab3b7c10b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Porcel JM. Minimally invasive treatment of complicated parapneumonic effusions and empyemas in adults. Clin Respir J 2018;12:1361\u20136.","DOI":"10.1111\/crj.12730"},{"key":"2025120909224052144_j_pp-2019-0027_ref_007_w2aab3b7c10b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"M\u00f8ller Gundersen K, Nygaard Jensen J, Bjerrum L, Hansen MP. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review. Basic Clin Pharmacol Toxicol 2019;124:550\u20139.","DOI":"10.1111\/bcpt.13205"},{"key":"2025120909224052144_j_pp-2019-0027_ref_008_w2aab3b7c10b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Vaughn VM, Flanders SA, Snyder A, Conlon A, Rogers MA, Malani AN, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: A multihospital cohort study. Ann Intern Med 2019;171:153\u201363.","DOI":"10.7326\/M18-3640"},{"key":"2025120909224052144_j_pp-2019-0027_ref_009_w2aab3b7c10b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Bhatnagar R, Skouras VS, Rahman NM, Psallidas I. Antibiotics for pleural infections. In: Aliberti S, Chalmers JD, Pletz MW, editors. Anti-infectives and the Lung (ERS Monograph). Sheffield, European Respiratory Society. 253\u201363, 2017. DOI:10.1183\/2312508X.10005816.","DOI":"10.1183\/2312508X.10005816"},{"key":"2025120909224052144_j_pp-2019-0027_ref_010_w2aab3b7c10b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest 2014;145:848\u201355.","DOI":"10.1378\/chest.13-1558"},{"key":"2025120909224052144_j_pp-2019-0027_ref_011_w2aab3b7c10b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Gjika E, Beaulieu JY, Vakalopoulos K, Gauthier M, Bouvet C, Gonzalez A, et al. Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial. Ann Rheum Dis 2019;78:1114\u201321.","DOI":"10.1136\/annrheumdis-2019-215116"},{"key":"2025120909224052144_j_pp-2019-0027_ref_012_w2aab3b7c10b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Davies HE, Davies RJ, Davies CW. BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65:ii41\u201353.","DOI":"10.1136\/thx.2010.137000"},{"key":"2025120909224052144_j_pp-2019-0027_ref_013_w2aab3b7c10b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Shen KR, Bribriesco A, Crabtree T, Denlinger C, Eby J, Eiken P, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 2017;153:e129\u2013e146.","DOI":"10.1016\/j.jtcvs.2017.01.030"},{"key":"2025120909224052144_j_pp-2019-0027_ref_014_w2aab3b7c10b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Birkenkamp K, O\u2019Horo JC, Kashyap R, Kloesel B, Lahr BD, Daniels CE, et al. Empyema management: A cohort study evaluating antimicrobial therapy. J Infect 2016;72:537\u201343.","DOI":"10.1016\/j.jinf.2016.02.009"},{"key":"2025120909224052144_j_pp-2019-0027_ref_015_w2aab3b7c10b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Suzuki H, Shomura S, Sawada Y, Shimamoto A, Kondo C, Takao M, et al. Therapeutic strategy for acute pleural empyema: comparison between retrospective study and prospective study. Gen Thorac Cardiovasc Surg 2019;67:1048\u201355.","DOI":"10.1007\/s11748-019-01134-2"},{"key":"2025120909224052144_j_pp-2019-0027_ref_016_w2aab3b7c10b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez MA, Cordero PJ, Cases E, Sanchis JL, Sanchis F, Ferrando D, et al. Prognostic features of residual pleural thickening in metapneumonic pleural effusion. Arch Bronconeumol 1999;35:108\u201312.","DOI":"10.1016\/S0300-2896(15)30287-8"},{"key":"2025120909224052144_j_pp-2019-0027_ref_017_w2aab3b7c10b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Castro D, D\u00edaz G, P\u00e9rez-Rodr\u00edguez E, Light RW. Prognostic features of residual pleural thickening in parapneumonic pleural effusions. Eur Respir J 2003;21:952\u20135.","DOI":"10.1183\/09031936.03.00099502"},{"key":"2025120909224052144_j_pp-2019-0027_ref_018_w2aab3b7c10b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Alem\u00e1n C, Porcel JM, Alegre J, Ruiz E, Bielsa S, Andreu J, et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung 2015;193:993\u20131000.","DOI":"10.1007\/s00408-015-9807-6"},{"key":"2025120909224052144_j_pp-2019-0027_ref_019_w2aab3b7c10b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Porcel JM, Valencia H, Bielsa S. Manual intrapleural saline flushing plus urokinase: a potentially useful therapy for complicated parapneumonic effusions and empyemas. Lung 2017;195:135\u20138.","DOI":"10.1007\/s00408-016-9964-2"},{"key":"2025120909224052144_j_pp-2019-0027_ref_020_w2aab3b7c10b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011;365:518\u201326.","DOI":"10.1056\/NEJMoa1012740"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/5\/1\/article-20190027.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0027\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0027\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:57:25Z","timestamp":1765277845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0027\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3,26]]}},"alternative-id":["10.1515\/pp-2019-0027"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0027","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"article-number":"20190027"}}